Background Document for “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019-20 Influenza Season”

Español | Other Languages
Print

Pages in this Report

  1. Background and Epidemiology
  2. Immunogenicity, Efficacy, and Effectiveness of Influenza Vaccines
  3. Safety of Influenza Vaccines
  4. References
  5. Links to Current and Past Guidance
  6. Table
Related Pages

Introduction

This document contains background material relevant to “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019-20 Influenza Season” (MMWR Recomm Rep 2019;68[No.RR-3]). The above-referenced document contains the CDC/ACIP recommendations for use of influenza vaccines in various populations for the 2019-20 season, methods for the development of recommendations, discussion of vaccines expected to be available, contraindications and precautions to vaccination, and relevant figures and tables. This document contains additional background references concerning these topics.

Abbreviations
  • ACIP:  Advisory Committee on Immunization Practices
  • AE:  Adverse event
  • aIIV3:  Adjuvanted trivalent inactivated influenza vaccine
  • ARI:  Acute respiratory illness
  • ccIIV4:  Mammalian cell culture-based quadrivalent inactivated influenza vaccine
  • CDC:  U.S. Centers for Disease Control and Prevention
  • CI:  Confidence Interval
  • CMS:  U.S. Centers for Medicare and Medicaid Services
  • FDA:  U.S. Food and Drug Administration
  • GMT:  Geometric mean titer
  • HA:  Hemagglutinin
  • HD-IIV3:  Trivalent high-dose inactivated influenza vaccine
  • ICU:  Intensive care unit
  • IIV:  Inactivated Influenza Vaccine (trivalent or quadrivalent)
  • IIV3:  Trivalent inactivated influenza vaccine
  • IIV4:  Quadrivalent inactivated influenza vaccine
  • ILI:  Influenza-like illness
  • LAIV:  Live attenuated influenza vaccine (trivalent or quadrivalent)
  • LAIV3:  Trivalent live attenuated influenza vaccine
  • LAIV4:  Quadrivalent live attenuated influenza vaccine
  • LCI:  Laboratory-confirmed influenza
  • MAARI:  Medically-attended acute respiratory illness
  • MI:  Myocardial infarction
  • Mos:  Months
  • NA:  Neuraminidase
  • P&I:  Pneumonia and influenza
  • RIV:  Recombinant influenza vaccine (trivalent or quadrivalent)
  • RIV3:  Trivalent recombinant influenza vaccine
  • RIV4:  Quadrivalent recombinant influenza vaccine
  • SAE:  Serious adverse event
  • SD-IIV:  Standard-dose inactivated influenza vaccine (generally used when necessary to distinguish from high-dose inactivated influenza vaccine).
  • TND:  Test-negative design
  • VAERS:  Vaccine Adverse Event Reporting System
  • VSD:  Vaccine Safety Datalink
  • Yrs:  years